On 2025-11-13, the U.S. Food and Drug Administration (FDA) officially revised the prescribing information for Liraglutide, adding a prominent Boxed Warning to its label. This significant update alerts healthcare professionals and patients to the potential risk of thyroid C-cell tumors. The warning is based on findings from preclinical studies, which demonstrated that Liraglutide induced dose-dependent and treatment-duration-dependent thyroid C-cell tumors in both male and female rats and mice at exposures considered clinically relevant.
Background
Liraglutide is a pharmaceutical agent available under various brand names, including Xultophy 100/3.6, Saxenda, and Victoza. It is also formulated in combination with insulin degludec. The implementation of a Boxed Warning represents the highest level of warning that the FDA can mandate for a prescription drug, indicating serious or potentially life-threatening risks. This specific warning highlights a concern identified in animal models, where Liraglutide was found to cause thyroid C-cell tumors.
What this means
The inclusion of a Boxed Warning on the Liraglutide label requires prescribers to be fully aware of the identified risk of thyroid C-cell tumors. This warning is a critical piece of information for conducting a thorough risk-benefit analysis for each patient before initiating or continuing treatment with Liraglutide. The data supporting this warning indicates that Liraglutide led to the development of thyroid C-cell tumors in a manner that was dependent on both the dose administered and the duration of treatment in animal studies involving both genders of rats and mice. These tumors occurred at exposures that are considered relevant to human clinical use. Consequently, clinicians should counsel patients about this potential risk and monitor for any signs or symptoms related to thyroid C-cell tumors.
Source
The details of this label revision were obtained from the FDA. The update, which includes the addition of a Boxed Warning concerning the risk of thyroid C-cell tumors for Liraglutide, became effective on 2025-11-13. Further information can be verified through the official FDA records available on dailymed.nlm.nih.gov.